An observational study in Hematologic Neoplasms and Burns, sponsored by Hemanext. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Hemanext · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.
The primary objective is to assess hypoxic RBCs safety and tolerance assessment up to 24 hours following the transfusion initiation and overall up to 7 days (+/- 1 day) after the transfusion episode (single transfusion course).
Secondary objectives include the following.
Assessment of AEs occurrence:
i. Up to 7 days (+/- 1 day) post transfusion, in comparison with historical control (including but not limited to infection, deep vein thrombosis, acute respiratory distress syndrome, transfusion-related acute lung injury, transfusion associated circulatory overload, anaphylactic shock, acute hemolytic transfusion reaction).
ii. Up to the subsequent transfusion episode or up to 28 days (+/- 1 day) after the initial transfusion, whichever comes first.
iii. From enrollment, up to their subsequent transfusion or 28 days (+/- 1 day) post transfusion, whichever comes first, through the assessment of patient's diary.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
This study's enrollment of 22 is below the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →Hemanext is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
10 acute burn patients and 10 patients with hematological malignancies, who require transfusion of red cells concentrates and who fulfill all eligibility criteria will be enrolled in this clinical investigation at Haukeland University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A. Hematological patients group:
B. Burn patients group:
Exclusion Criteria:
A. Both patients groups
B. Burn patients specific exclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects requiring chronic transfusions with red blood cells for treatment of a hematologic malignancy will receive 1 transfusion with 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. The subjects will be monitored for all adverse events from Informed Consent through Day 28 or the subsequent standard of care transfusion, whichever occurs first.
Device: Hypoxic Red Blood Cells
Subjects requiring transfusion with red blood cells during the excision procedure after an acute burn will receive 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. As the excision treatments require transfusion of more than 2 units of red blood cells, the first 2 units transfused during the procedure will be hypoxic red blood cells. The subjects will be monitored for all adverse events through Day 28.
Device: Hypoxic Red Blood Cells
Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion.
The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions
Time frame: 24 hours
Number of Participants Who Experienced an Adverse Event (AE) (All Types/Grades) Overall up to 7 Days (+/-1 Day) After the Transfusion.
The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions
Time frame: 7 days (+/-1 day)
Evolution of the Hemoglobin Level Before and After the Transfusion.
The difference in measured hemoglobin (grams/dL) between pre-transfusion and up to 30 minutes post-transfusion.
Time frame: pre-transfusion to up to 30 minutes post-transfusion
Calculation of the Hemoglobin Increment After Transfusion Corrected for Patient Blood Volume and Hemoglobin Dose
The hemoglobin increment from each transfusion will be determined by calculating the difference between the subject's post-transfusion and pre-transfusion hemoglobin (g/dL). It will then be corrected for estimated subject blood volume and the amount of Hb transfused. The following equation used for the hemoglobin increment calculation: HgB Increment = (Subject's HgB level post-transfusion - Subject's HgB pre-transfusion)/ (total HgB transfused x Subject's BloodVolume) Equations for calculating the hemoglobin increment may be found in the following publication: Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H. Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29. PMID: 30159896.
Time frame: 28 days
Comparison of the Hemoglobin Level Before the Index Transfusion to That Prior to the Subsequent Transfusion
The difference in measured hemoglobin (grams/dL) between the pre-transfusion hemoglobin level for the study transfusion and the pre-transfusion hemoglobin level for the next scheduled transfusion.
Time frame: 28 days
Evaluation of AEs From Enrollment, up to Prior to the Subsequent Transfusion or up to Day 28, Whichever Occurs First
Number of AEs that occur from enrollment, up to prior to the subsequent transfusion or up to Day 28, whichever occurs first
Time frame: 28 days
Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
Change in blood pressure (systolic; mmHg) from baseline up to 15 minutes post-transfusion.
Time frame: baseline up to 15 minutes post-transfusion.
Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
Change in blood pressure (diastolic; mmHg) from baseline up to 15 minutes post-transfusion.
Time frame: baseline up to 15 minutes post-transfusion.
Evaluation of Subject's Respiratory Rate Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
Change in respiratory rate (breaths per minute) from baseline to up to 15 minutes post-transfusion.
Time frame: baseline to up to 15 minutes post-transfusion
Evaluation of Subject's SO2 Level Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
Change in the amount of oxygen in the body (% S02 level), measured with a pulse oximeter, from baseline to up to 15 minutes post-transfusion.
Time frame: baseline to up to 15 minutes post-transfusion
Evaluation of Subject's Pulse Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
Change in heart rate (beats per minute) from baseline to up to 15 minutes post-transfusion
Time frame: baseline to up to 15 minutes post-transfusion
| Milestone | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Started | 10 | 12 |
| Completed | 9 | 10 |
| Not completed | 1 | 2 |
The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions
| Participants | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion. | 2 | 3 |
The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions
| Participants | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) (All Types/Grades) Overall up to 7 Days (+/-1 Day) After the Transfusion. | 4 | 7 |
The difference in measured hemoglobin (grams/dL) between pre-transfusion and up to 30 minutes post-transfusion.
| g/dL | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Evolution of the Hemoglobin Level Before and After the Transfusion. | 1.20 ± 0.494 | 0.25 ± 0.981 |
The hemoglobin increment from each transfusion will be determined by calculating the difference between the subject's post-transfusion and pre-transfusion hemoglobin (g/dL). It will then be corrected for estimated subject blood volume and the amount of Hb transfused. The following equation used for the hemoglobin increment calculation: HgB Increment = (Subject's HgB level post-transfusion - Subject's HgB pre-transfusion)/ (total HgB transfused x Subject's BloodVolume) Equations for calculating the hemoglobin increment may be found in the following publication: Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H. Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29. PMID: 30159896.
No measurements were reported for this outcome.
The difference in measured hemoglobin (grams/dL) between the pre-transfusion hemoglobin level for the study transfusion and the pre-transfusion hemoglobin level for the next scheduled transfusion.
| g/dL | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Comparison of the Hemoglobin Level Before the Index Transfusion to That Prior to the Subsequent Transfusion | 0.21 ± 1.177 | 0.84 ± 2.065 |
Number of AEs that occur from enrollment, up to prior to the subsequent transfusion or up to Day 28, whichever occurs first
| adverse event | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Evaluation of AEs From Enrollment, up to Prior to the Subsequent Transfusion or up to Day 28, Whichever Occurs First | 4 | 7 |
Change in blood pressure (systolic; mmHg) from baseline up to 15 minutes post-transfusion.
| mmHg | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion | -4.56 ± 6.521 | -3.40 ± 23.996 |
Change in blood pressure (diastolic; mmHg) from baseline up to 15 minutes post-transfusion.
| mmHg | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion | -0.44 ± 7.333 | 1.90 ± 9.219 |
Change in respiratory rate (breaths per minute) from baseline to up to 15 minutes post-transfusion.
| breaths/min | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Evaluation of Subject's Respiratory Rate Over the Course of the Transfusion and up to 15 Minutes Post-transfusion | 0.00 ± 2.062 | -1.10 ± 2.846 |
Change in the amount of oxygen in the body (% S02 level), measured with a pulse oximeter, from baseline to up to 15 minutes post-transfusion.
| % O2 saturation | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Evaluation of Subject's SO2 Level Over the Course of the Transfusion and up to 15 Minutes Post-transfusion | 0.22 ± 1.856 | 0.00 ± 1.633 |
Change in heart rate (beats per minute) from baseline to up to 15 minutes post-transfusion
| beats/min | Hematologic Malignancies | Acute Burn |
|---|---|---|
| Evaluation of Subject's Pulse Over the Course of the Transfusion and up to 15 Minutes Post-transfusion | -3.33 ± 6.144 | 5.40 ± 16.263 |
Collected over Adverse Events reported up to 28 days post-transfusion, or up to subsequent transfusion episode, whichever comes first. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hematologic Malignancies | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Acute Burn | 0/12 (0%) | 1/12 (8.3%) | 6/12 (50%) |
| Event | Hematologic Malignancies | Acute Burn |
|---|---|---|
| OliguriaRenal and urinary disorders | 0/10 | 1/12 |
| Wound infectionInfections and infestations | 0/10 | 1/12 |
| Event | Hematologic Malignancies | Acute Burn |
|---|---|---|
| PyrexiaGeneral disorders | 1/10 | 3/12 |
| NasopharyngitisInfections and infestations | 2/10 | 0/12 |
| HeadacheNervous system disorders | 2/10 | 0/12 |
| PruritusSkin and subcutaneous tissue disorders | 0/10 | 2/12 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/10 | 0/12 |
| Atrial fibrillationCardiac disorders | 1/10 | 0/12 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/10 | 0/12 |
| Catheter site extravasationGeneral disorders | 0/10 | 1/12 |
| Pain of skinSkin and subcutaneous tissue disorders | 0/10 | 1/12 |
| RashSkin and subcutaneous tissue disorders | 0/10 | 1/12 |
| Age, Categorical(Participants) | Hematologic Malignancies | Acute Burn | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 10 | 12 |
| >=65 years | 8 | 2 | 10 |
| Age, Continuous(years) | Hematologic Malignancies | Acute Burn | Total |
|---|---|---|---|
| Mean | 72.0 ± 16.41 | 49.6 ± 19.46 | 59.8 ± 21.08 |
| Sex: Female, Male(Participants) | Hematologic Malignancies | Acute Burn | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 8 | 10 | 18 |
| Race (NIH/OMB)(Participants) | Hematologic Malignancies | Acute Burn | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 10 | 11 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Hematologic Malignancies | Acute Burn | Total |
|---|---|---|---|
| Norway | 10 | 12 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in May 2024, 20 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 186 observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hemanext